Literature DB >> 11287414

Class I major histocompatibility complex anchor substitutions alter the conformation of T cell receptor contacts.

A K Sharma1, J J Kuhns, S Yan, R H Friedline, B Long, R Tisch, E J Collins.   

Abstract

An immunogenic peptide (GP2) derived from HER-2/neu binds to HLA-A2.1 very poorly. Some altered-peptide ligands (APL) of GP2 have increased binding affinity and generate improved cytotoxic T lymphocyte recognition of GP2-presenting tumor cells, but most do not. Increases in binding affinity of single-substitution APL are not additive in double-substitution APL. A common first assumption about peptide binding to class I major histocompatibility complex is that each residue binds independently. In addition, immunologists interested in immunotherapy frequently assume that anchor substitutions do not affect T cell receptor contact residues. However, the crystal structures of two GP2 APL show that the central residues change position depending on the identity of the anchor residue(s). Thus, it is clear that subtle changes in the identity of anchor residues may have significant effects on the positions of the T cell receptor contact residues.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11287414     DOI: 10.1074/jbc.M010791200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

Review 1.  Rational design of peptide-based tumor vaccines.

Authors:  Wilson S Meng; Lisa H Butterfield
Journal:  Pharm Res       Date:  2002-07       Impact factor: 4.200

2.  Conformational melding permits a conserved binding geometry in TCR recognition of foreign and self molecular mimics.

Authors:  Oleg Y Borbulevych; Kurt H Piepenbrink; Brian M Baker
Journal:  J Immunol       Date:  2011-01-31       Impact factor: 5.422

3.  Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design.

Authors:  Oleg Y Borbulevych; Tiffany K Baxter; Zhiya Yu; Nicholas P Restifo; Brian M Baker
Journal:  J Immunol       Date:  2005-04-15       Impact factor: 5.422

Review 4.  Improving T cell responses to modified peptides in tumor vaccines.

Authors:  Jonathan D Buhrman; Jill E Slansky
Journal:  Immunol Res       Date:  2013-03       Impact factor: 2.829

5.  Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines.

Authors:  Rachel H McMahan; Jennifer A McWilliams; Kimberly R Jordan; Steven W Dow; Darcy B Wilson; Jill E Slansky
Journal:  J Clin Invest       Date:  2006-08-24       Impact factor: 14.808

6.  Modeling Sequence-Dependent Peptide Fluctuations in Immunologic Recognition.

Authors:  Cory M Ayres; Timothy P Riley; Steven A Corcelli; Brian M Baker
Journal:  J Chem Inf Model       Date:  2017-07-25       Impact factor: 4.956

7.  Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition.

Authors:  Oleg Y Borbulevych; Francis K Insaidoo; Tiffany K Baxter; Daniel J Powell; Laura A Johnson; Nicholas P Restifo; Brian M Baker
Journal:  J Mol Biol       Date:  2007-07-26       Impact factor: 5.469

Review 8.  Conformational changes and flexibility in T-cell receptor recognition of peptide-MHC complexes.

Authors:  Kathryn M Armstrong; Kurt H Piepenbrink; Brian M Baker
Journal:  Biochem J       Date:  2008-10-15       Impact factor: 3.857

9.  Accurate structure prediction of peptide-MHC complexes for identifying highly immunogenic antigens.

Authors:  Min-Sun Park; Sung Yong Park; Keith R Miller; Edward J Collins; Ha Youn Lee
Journal:  Mol Immunol       Date:  2013-05-18       Impact factor: 4.407

Review 10.  Thermodynamics of T-cell receptor-peptide/MHC interactions: progress and opportunities.

Authors:  Kathryn M Armstrong; Francis K Insaidoo; Brian M Baker
Journal:  J Mol Recognit       Date:  2008 Jul-Aug       Impact factor: 2.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.